Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm.

Yang, Charlie; Brezden-Masley, Christine; Joy, Anil Abraham; Sehdev, Sandeep; Modi, Shanu; Simmons, Christine; Henning, Jan-Willem

Yang, Charlie; Brezden-Masley, Christine; Joy, Anil Abraham; Sehdev, Sandeep; Modi, Shanu; Simmons, Christine; Henning, Jan-Willem.

Afiliación

Yang C; Tom Baker Cancer Centre, University of Calgary, 1331 29 Street NW, Calgary, AB T2N 4N2, Canada.
Brezden-Masley C; Sinai Health System, Mountain Sinai Hospital, University of Toronto, Toronto, ON, Canada.
Joy AA; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Sehdev S; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.
Modi S; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Simmons C; BC Cancer Agency - Vancouver Centre, University of British Columbia, Vancouver, BC, Canada.
Henning JW; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.

Ther Adv Med Oncol ; 15: 17588359231175440, 2023.

Article en En | MEDLINE | ID: mdl-37323186

Palabras clave

HER2-low; HER2-targeted therapy; chemotherapy; metastatic breast cancer; sacituzumab govitecan; trastuzumab deruxtecan; treatment sequencing

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Ther Adv Med Oncol Año: 2023 Tipo del documento: Article País de afiliación: Canadá